Adhera Therapeutics, Inc.

Equities

ATRX

US00687E4061

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:17:04 2024-06-11 pm EDT			5-day change	1st Jan Change
0.0043 ^USD	+2.38%		+4.88%	-85.67%

Jan. 18	Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	CI
Jan. 16	Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	CI

Adhera Therapeutics, Inc. Appoints Andrew Kucharchuk as the Chief Executive Officer

July 13, 2020 at 07:58 am EDT

On July 7, 2020, the Board of Directors of Adhera Therapeutics, Inc. engaged Mr. Andrew Kucharchuk to serve as the Chief Executive Officer of the Company effective immediately. Mr. Kucharchuk, previously served as President and Chief Financial Officer of OncBioMune Pharmaceuticals, Inc. from February 2016 until June 2020.

Latest news about Adhera Therapeutics, Inc.

Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	Jan. 18	CI
Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	Jan. 16	CI
Adhera Therapeutics, Inc. Announces Board Resignations	Jan. 16	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Adhera Therapeutics, Inc. announced that it has received $0.105 million in funding	23-06-21	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	23-04-27	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Adhera Therapeutics, Inc. announced that it has received $0.214285 million in funding	23-03-01	CI
Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding	23-02-15	CI
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes	23-01-25	CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	22-12-14	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Adhera Therapeutics, Inc. Elects Zahed Subhan as Chairman of the Board	22-09-19	CI
Adhera Therapeutics, Inc. Announces CEO Changes, Effective September 30, 2022	22-09-09	CI
Adhera Therapeutics, Inc. Appoints Andrew Kucharchuk as Chief Operating Officer, Effective September 30, 2022	22-09-09	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Adhera Therapeutics, Inc. enter into letter of intent to acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin from Bio Innovation Group.	22-07-18	CI
Adhera Therapeutics, Inc. Planning to Initiate A Phase 2 Clinical Trial of Mlr-1023 as new Treatment for Type 1 Diabetes	22-05-19	CI
Adhera Therapeutics, Inc. Appoints Trond K. Waerness as Chairman of the Board	22-05-19	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI

Chart Adhera Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADHERA THERAPEUTICS, INC.	-85.67%	50K
VERTEX PHARMACEUTICALS INCORPORATED	+16.93%	123B
REGENERON PHARMACEUTICALS, INC.	+17.01%	111B
BIONTECH SE	-7.23%	23.63B
ARGENX SE	+2.59%	22.58B
GENMAB A/S	-14.99%	17.26B
BEIGENE, LTD.	-6.79%	17.6B
WUXI APPTEC CO., LTD.	-37.63%	17.61B
NEUROCRINE BIOSCIENCES, INC.	+2.17%	13.55B
SAREPTA THERAPEUTICS, INC.	+24.42%	11.34B

Bio Therapeutic Drugs